Read More

JNJ Rybrevant Receives Canadian Agency For Drugs and Technologies In Health Reimbursement Recommendation For The Treatment Of Adult Patients With Non-Small Cell Lung Cancer With Activating EGFR Exon 20 Insertion Mutations

Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Canadian Agency for Medicines and Health Technologies ( ACMTS ) recommended that RYBREVANT® ( amivantamab ) be reimbursed by public schemes for the treatment of adult patients with non-small cell lung cancer ( CPNPC ) locally advanced or metastatic, carriers of activating mutations for the insertion of exon 20 of the e

JNJ